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Abstract: Targeted therapy has become a valuable approach in adeno-
carcinoma of the lung. The number of actionable mutations has been 
continuously increasing with significant acceleration from discovery 
to clinical application. Herein, we present a case of innovative treat-
ment using targeted therapy of a 75-year-old female with two primary 
adenocarcinomas of the lung. The first tumor was found to carry 
an activating mutation in the exon 19 of the epidermal growth fac-
tor receptor and responded favorably to treatment with erlotinib. The 
second primary tumor was found to carry an isolated amplification 
of the c-met gene but no epidermal growth factor receptor mutation. 
Off-label use of crizotinib, a potent inhibitor of c-met, was prescribed. 
Within 4 weeks of treatment initiation, the tumor and the dependent 
lymphadenopathy responded with rapid shrinkage. This observation 
stresses the need for rebiopsy of tumors upon progression or change 
of biological behavior for selection of appropriate targeted therapy.
The discovery of new “driver mutations” has augmented the therapeutic armamentarium for the treatment of lung can-
cer.1 We herein describe an interesting case of rapid response 
to crizotinib in a de novo c-met–amplified adenocarcinoma 
in a patient with a pre-existing adenocarcinoma of the lung 
carrying an activating mutation in exon 19 of the epidermal 
growth factor receptor (EGFR). A left lower lobe (LLL) lung 
mass, several indeterminate pulmonary nodules, and a lytic 
spinal lesion were discovered in a 75-year-old female on 
annual surveillance in follow-up for early-stage breast cancer 
that had been surgically treated 7 years ago. The patient had a 
40-pack-year smoking history and an excellent performance 
status (Eastern Cooperative Oncology Group, 0–1). Medical 
history was significant for bilateral breast cancer (2002 and 
2004) and a well-differentiated papillary carcinoma of the 
thyroids (2008), all of which were treated surgically and were 
in remission. The patient had no significant active medical 
conditions. A biopsy of the LLL mass was done and found 
to be morphologically compatible with a moderately-to-well-
differentiated adenocarcinoma. Immunohistochemical analy-
sis revealed diffuse positivity for thyroid transcription factor 1 
(TTF-1) and napsin A. The tumor was negative for mammaglo-
bin, estrogen receptor, and progesterone receptor expression. 
This immunoprofile supports the diagnosis of an adenocar-
cinoma of pulmonary origin. The molecular profile revealed 
an activating mutation in exon 19 of the EGFR with deletion 
of amino acids 746 through 750. Polymerase chain reaction 
and Sanger DNA sequencing were used to detect these muta-
tions. Erlotinib was initiated with good partial radiographic 
response based on the Response Evaluation Criteria in Solid 
Tumors 1.1 criteria (Fig. 1, upper panel). After 3 months of 
treatment, an enlarging right upper lobe (RUL) lesion and 
adjacent lymphadenopathy were discovered on follow-up 
computed tomography scans of the chest (Fig. 1, lower panel). 
The other tumor lesions remained stable. A biopsy of this 
enlarging RUL lesion was done and confirmed morphologi-
cally to be a poorly differentiated carcinoma with solid growth 
pattern. Immunohistochemical studies demonstrated tumor 
cells with diffusely positive staining for CK7 and patchy posi-
tive pattern for TTF-1 staining, whereas CK20, napsin A, p63, 
CK5/6, estrogen receptor, progesterone receptor, PAX8, Gata-
3, and CDX2 were not detected. Taken together, the morpho-
logic features and immunoprofile are consistent with poorly 
differentiated adenocarcinoma of lung primary (Fig. 2).
Molecular examination of the erlotinib-refractory 
RUL mass for resistance markers to EGFR inhibition was 
negative for any EGFR mutation, including the previously 
detected exon 19 or a T790M mutation; however, high levels 
of c-met amplification were discovered. C-met amplifica-
tion is a well-established mechanism of resistance to treat-
ment with EGFR inhibitors2 and part of our institutional 
reflex panel in setting of resistance to EGFR inhibitor. The 
amplification of c-met, semiquantitated by fluorescence in 
situ hybridization, revealed a c-met/CEP7 ratio of 6.5 in the 
background of a diploid chromosome 7, therefore suggesting 
true amplification at a high level. DNA sequencing of EGFR 
exons 18 through 21 revealed a wild-type genotype. Because 
the EGFR mutation was felt to be the driver mutation in 
the LLL lesion, and no mutation of EGFR was found in the 
RUL lesion, the RUL tumor was felt to be a distinct second 
primary adenocarcinoma of the lung and propagated by a 
different molecular pathway. Of note, anaplastic lymphoma 
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kinase fusion was not detected in either biopsy specimen.3 
After presenting this case in our institutional tumor board 
and discussion with the patient, off-label use of crizotinib in 
this setting was pursued based on early phase I trial data pre-
sented at this year’s American Society of Clinical Oncology 
meeting.4
Crizotinib is a potent multikinase inhibitor with abil-
ity to block c-met activation in the low nanomolar range. 
The phase I study suggested a good correlation between 
level of c-met amplification and response to crizotinib.4 
Therefore, crizotinib was initiated in addition to con-
tinuation of erlotinib, which was given the first primary 
FIGURE 1.  Radiographic evaluation of left lower lobe (LLL) (upper series) and right upper lobe (RUL) (lower series). The lesions 
that have taken for biopsy are marked by arrows. The timeline refers to time since initial diagnosis of LLL lesion. The upper series 
demonstrates continuous shrinkage after initiation of erlotinib. The patchy infiltrates at 7 months are biopsy proven to be bron-
chiolitis obliterans organizing pneumonia. The lower series demonstrates an RUL lesion with interval growth between baseline 
and 5 months, followed by significant shrinkage after initiation of crizotinib. *The 2-week time frame of drug discontinuation 
due to transaminitis.
FIGURE 2.  Morphologic features and immunohistochemical stains for left lower lobe (LLL) (A–C) and right upper lobe (RUL) 
(D–F) tumors. Hematoxylin and eosin stains for LLL (A) and RUL (D). Positive TTF-1 stains in LLL (B) and RUL (E). Positive napsin 
A staining in LLL (C) and negative staining in RUL (F).
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adenocarcinoma carrying an activating EGFR mutation, 
which she had previously tolerated well.
After 4 weeks of treatment, the c-met–amplified tumor 
had shrunk by more than 50% in maximum dimension, con-
sistent with a good partial response. Dependent hilar lymph-
adenopathy equally responded with significant size reduction. 
On therapy with combined crizotinib and erlotinib, the patient 
also experienced a significant increase in toxicity, including a 
mild case of biopsy-proven bronchiolitis obliterans organizing 
pneumonia without significant clinical pulmonary symptoms 
and grade 3 transaminitis. The patient was seen by our pulmo-
nary services and was felt to be appropriate for observation and 
continuation of drug therapy. Her transaminitis resolved with 
discontinuation within 2 weeks and remained without recur-
rence on subsequent dose reduction (both erlotinib [75 mg/
day] and crizotinib [250 mg/day] were adjusted by 50%). She 
has since continued both medications for 2 months with lower 
extremity edema being the only noticeable adverse event. The 
increase in drug-related toxicity may be related to synergistic 
effects of multikinase pathway inhibition on combination ther-
apy or alternatively through increased plasma levels as a result 
of competitive inhibition of the cytochrome p450 3A4 sys-
tem, a mechanism through which both drugs are metabolized. 
Theoretically, this could lead to higher plasma levels of both 
crizotinib and erlotinib. It is of note that the EGFR-mutated 
LLL lesion, which initially responded to treatment with a good 
partial response and then stabilized its radiographic appear-
ance, demonstrated further improvement in radiographic 
appearance after initiation of crizotinib (Fig. 1). It remains 
speculative whether increasing plasma levels of erlotinib, addi-
tional pathway inhibition through crizotinib, or a combination 
of both are responsible for this observation. The c-met path-
way also intersects with multiple other signaling pathways, 
including EGFR. In preclinical models, concurrent EGFR/c-
met inhibition showed increased antitumor activity, enhanced 
erlotinib sensitivity, and applied negative selection pressure 
against clones with c-met amplification upon continued stimu-
lation with hepatocyte growth factor. It is also conceivable that 
the LLL lesion may have carried a secondary alteration within 
the c-met pathway which could explain further shrinkage; how-
ever, this testing was not done in the absence of a clinical indi-
cation with ongoing response to erlotinib.
In summary, this case provides further evidence of c-met 
as a primary driver mutation in adenocarcinomas of the lung. 
It further underlines the efficacy of crizotinib in c-met–driven 
tumors, especially those with high levels of amplification that 
was previously reported by Camidge et al. Moreover, this case 
stresses the importance of molecular re-evaluation by repeat 
biopsy in the context of disease progression and change in clin-
ical behavior. As in our case, the possibility of a synchronous 
multiple primary lung cancer with a second driver mutation 
should be considered as it may provide additional therapeutic 
opportunities. This approach will require further verification 
the detection of early pulmonary carcinomas is expected to rise 
with increased screening efforts and improved survival.
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